Qin Wei, Chen Meiyu, Cai Xiaohui, Chao Hongying, Liu Jie, Jiang Naike, Zhou Min, Lu Xuzhang, Chen Suning, Zhang Ri, He Chuan, Wang Qian
Department of Hematology, the Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, Jiangsu 213003, China, Email:
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019 Sep 10;36(9):857-861. doi: 10.3760/cma.j.issn.1003-9406.2019.09.001.
To carry out mutation analysis for patients with myelodysplastic syndromes (MDS) and a normal karyotype.
Targeted capture and next-generation sequencing (NGS) was carried out using a customized 49-gene panel. FLT3 internal tandem duplication (FLT3-ITD), CALR, NPM1 and CEBPA mutations were detected by PCR and Sanger sequencing.
Sixty-two patients (80.5%) were found to harbor at least one mutation. Each patient has carried 2.21 mutations in average. Coexistence of ≥ 3 mutations was common (43.7%). The most commonly mutated genes were RUNX1 (23.4%, 18/77), ASXL1 (18.2%, 14/77), NPM1 (15.6%, 12/77), U2AF1 (15.6%, 12/77), DNMT3A (11.7%, 9/77). Patients with SF3B1 mutations were significantly older than those with ASXL1 mutations (P=0.023). Mutations of the DNMT3A gene were significantly associated with the blood platelet level compared with BCOR mutations (P=0.02). No significant difference was found in the number and rate of mutations between those under or above 60-year-old. Among 67 patients with clinical follow-up, 20 (29.8%) has transformed to acute myeloid leukemia, and the time of transformation has ranged from 1 to 44 months, with a average of 5.3 months. RUNX1, U2AF1 and FLT3 mutations are associated with leukemic transformation.
Coexistence of ≥ 3 mutations are frequent among patients with normal-karyotype MDS. Certain mutations are associated with age and leukemic transformation.
对核型正常的骨髓增生异常综合征(MDS)患者进行突变分析。
使用定制的49基因panel进行靶向捕获和二代测序(NGS)。通过PCR和Sanger测序检测FLT3内部串联重复(FLT3-ITD)、CALR、NPM1和CEBPA突变。
62例患者(80.5%)被发现至少携带一种突变。每位患者平均携带2.21种突变。≥3种突变共存很常见(43.7%)。最常发生突变的基因是RUNX1(23.4%,18/77)、ASXL1(18.2%,14/77)、NPM1(15.6%,12/77)、U2AF1(15.6%,12/77)、DNMT3A(11.7%,9/77)。携带SF3B1突变的患者比携带ASXL1突变的患者年龄显著更大(P=0.023)。与BCOR突变相比,DNMT3A基因突变与血小板水平显著相关(P=0.02)。60岁以下和60岁以上患者的突变数量和突变率无显著差异。在67例有临床随访的患者中,20例(29.8%)已转化为急性髓系白血病,转化时间为1至44个月,平均为5.3个月。RUNX1、U2AF1和FLT3突变与白血病转化相关。
核型正常的MDS患者中≥3种突变共存很常见。某些突变与年龄和白血病转化相关。